Wave Life Sciences, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Wave Life Sciences reported Q3 2026 net loss of $61.9M (vs. $53.9M in Q3 2025) on revenue of $13.2M (vs. $7.6M). Cash and marketable securities totaled $431.0M as of September 30, 2026, with expected runway into Q3 2028. GSK paid $12M milestone for selecting a Wave-designed GalNAc-siRNA candidate in September 2026, with three additional programs advancing; Wave is eligible for $330–375M per program in development/launch/commercial milestones plus tiered royalties. Lead pipeline: WVE-006 (AATD, RNA editing) planning registrational trial with FDA alignment for potential accelerated approval; WVE-007 (obesity, GalNAc-siRNA) dosing ongoing in Phase 2a monotherapy, initiated combination trial with tirzepatide, on track to initiate maintenance trial Q4 2026; WVE-008 (PNPLA3 liver disease, RNA editing) CTA filing on track for Q4 2026.
Why this rating
Clinical progress and FDA alignment are encouraging, but company burns ~$80M/quarter against $431M cash—18-month runway. GSK $12M milestone is <2% of cash; upside from pipeline modest relative to pre-clinical/early-stage risk and burn rate.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.